Bioequivalence Study Comparing Two Test Products With One Reference Product, All Containing 5 mg Yohimbine
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
- Type: Bioequivalence study in male healthy volunteers, therapeutical indication
(erectile disfunction) not studied
- Products, dosage, and route of administration:
- Test 1: Yohimbin "Spiegel"® (Desma GmbH, Germany), tablet containing 5 mg yohimbine
hydrochloride, oral administration
- Reference: Yocon-Glenwood® (Glenwood GmbH, Germany), tablet containing 5 mg
yohimbine hydrochloride, oral administration
- Duration of treatment:
2 single-dose administrations of 5 mg yohimbine hydrochloride each under fasting
conditions separated by a wash-out period of at least one week i.e. 6 treatment free
days between all administrations